Racial and ethnic disparities have been reported in clinical trial/research participation, utilization of autologous and allogeneic blood and marrow transplantation (BMT), and availability of allogeneic donors. We performed a population-based cohort study to investigate adult hematologic malignancy referrals to a US tertiary cancer center, utilization of BMT, and participation in clinical trial, survey, and biospecimen research by race. US Census Data and the New York State Public Access Cancer Epidemiology Database identified the racial distribution of the general population and new hematologic malignancy cases in the primary catchment area. From 2005 to 2011, 1106 patients aged 18 to 75 years were referred for BMT consultation; although t...
Background: Hematopoietic stem cell transplantation (HCT) is indicated for patients with higher-ris...
Background: There are documented ethnic disparities in cancer care access, use and clinical outcome...
Background: Racial and ethnic minority groups (REMGs) have low rates of inclusion in cancer trials. ...
AbstractRacial and ethnic disparities have been reported in clinical trial/research participation, u...
Racial and ethnic disparities have been reported in the utilization of autologous and allogeneic BMT...
Abstract Background Racial/ethnic disparities in the utilization of hematopoietic cell transplantati...
Georgia Southern Researcher Examines Racial Differences in the Utilization of Bone Marrow Transplant...
AbstractAutologous hematopoietic cell transplantation (AHCT) is an established therapy for multiple ...
Introduction: Previous literature suggests that allogeneic hematopoietic stem cell tr...
AbstractOutcome disparity associated with race or ethnicity in the United States has been observed i...
Background: Hematological malignancies are cancers that affect the blood, bone marrow, and lymph nod...
AbstractCosta et al. recently reported that racial disparities prevented nearly 40% of non-Hispanic ...
Background: Study populations in clinical research must reflect US changing demographics, especially...
Over the past decades, consistent studies have shown that race/ethnicity have a great impact on canc...
BackgroundStudy populations in clinical research must reflect US changing demographics, especially w...
Background: Hematopoietic stem cell transplantation (HCT) is indicated for patients with higher-ris...
Background: There are documented ethnic disparities in cancer care access, use and clinical outcome...
Background: Racial and ethnic minority groups (REMGs) have low rates of inclusion in cancer trials. ...
AbstractRacial and ethnic disparities have been reported in clinical trial/research participation, u...
Racial and ethnic disparities have been reported in the utilization of autologous and allogeneic BMT...
Abstract Background Racial/ethnic disparities in the utilization of hematopoietic cell transplantati...
Georgia Southern Researcher Examines Racial Differences in the Utilization of Bone Marrow Transplant...
AbstractAutologous hematopoietic cell transplantation (AHCT) is an established therapy for multiple ...
Introduction: Previous literature suggests that allogeneic hematopoietic stem cell tr...
AbstractOutcome disparity associated with race or ethnicity in the United States has been observed i...
Background: Hematological malignancies are cancers that affect the blood, bone marrow, and lymph nod...
AbstractCosta et al. recently reported that racial disparities prevented nearly 40% of non-Hispanic ...
Background: Study populations in clinical research must reflect US changing demographics, especially...
Over the past decades, consistent studies have shown that race/ethnicity have a great impact on canc...
BackgroundStudy populations in clinical research must reflect US changing demographics, especially w...
Background: Hematopoietic stem cell transplantation (HCT) is indicated for patients with higher-ris...
Background: There are documented ethnic disparities in cancer care access, use and clinical outcome...
Background: Racial and ethnic minority groups (REMGs) have low rates of inclusion in cancer trials. ...